18F-FDG PET/CT in multiple myeloma: critical insights and future directions
We read with interest the articles by Jung et al.  and Ripani et al.  recently published in this journal. These studies point out the prognostic impact of 18F-FDG PET/CT at diagnosis and for therapy assessment in patients with multiple myeloma (MM). They are also the most recent in a wave of published articles which particularly highlight the increased attention received by this imaging technique in this pathology over the last decade. However, we believe it necessary to draw the attention of readers who might be swept along by this prevailing view to the urgent need for standardization to enable the field to move forward. Consistent with previous experience in lymphomas, ensuring reproducibility by establishing clear guidelines  is warranted before 18F-FDG PET/CT can be used in everyday routine in MM patients, and such guidelines need to be fully endorsed by the haematology community. The main risk with this flow of publications is that we are drowned in the multitude...
This work was supported in part by grants from the French National Agency for Research (Investissements d’Avenir; IRON Labex grant no. ANR-11-LABX-0018-01, and ArronaxPlus Equipex grant no. ANR-11-EQPX-0004), and from the Institut National du Cancer (grant no. INCa-DGOS-Inserm_12558, SIRIC ILIAD).
Compliance with ethical standards
Conflicts of interest
This article does not describe any studies with human participants performed by any of the authors.
- 2.Ripani D, Caldarella C, Za T, Pizzuto DA, Rossi E, De Stefano V, et al. Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation. Eur J Nucl Med Mol Imaging. 2019;46:116–28.CrossRefGoogle Scholar
- 8.Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911–8. https://doi.org/10.1200/JCO.2017.72.2975.CrossRefGoogle Scholar
- 20.Carlier T, Bailly C. State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET. Front Med (Lausanne). 2015;2:18.Google Scholar
- 22.Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40:1771–7.Google Scholar
- 24.Zamagni E, Nanni C, Dozza L, Carlier T, Tacchetti P, Versari A, et al. Standardization of 18F-FDG PET/CT according to Deauville criteria for MRD evaluation in newly diagnosed transplant eligible multiple myeloma patients: joined analysis of two prospective randomized phase III trials. Blood. 2018;132:257.Google Scholar